VERAXA Biotech AG (NASDAQ: VRXA) has commenced trading on the Nasdaq Capital Market following the completion of its business combination with Voyager Acquisition Corp., marking a milestone for the biotechnology company focused on next-generation antibody-based therapeutics for solid tumors. The company’s stock began trading under the ticker symbol VRXA on June 11, 2026.
VERAXA is advancing a diversified oncology pipeline covering monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The company’s BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, aiming to improve target specificity and reduce off-tumor toxicity—a key challenge in cancer treatment.
The company’s focus on ADCs and T-cell engagers (TCEs) places it within two rapidly growing segments of the global oncology therapeutics market. According to the company, VERAXA also aims to contribute value through selected partnerships in complementary therapeutic sectors such as radioimmunoconjugates (RICs) and antibody-oligonucleotide conjugates (AOCs).
VERAXA’s vision is to deliver smart cancer therapies with curative potential, targeting solid tumors that represent significant unmet medical needs. The company’s pipeline and platform technology are central to its strategy to develop treatments that are both more effective and safer than current options.
For investors, the listing on Nasdaq provides a public market for trading VERAXA shares, offering liquidity and visibility. The company’s focus on innovative ADC and TCE technologies aligns with industry trends toward precision oncology, potentially impacting treatment paradigms for various cancers. As VERAXA progresses its pipeline through clinical development, its success could influence the competitive landscape in oncology therapeutics.
The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
